Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer
First and only PARP inhibitor to improve invasive disease-free survival in patients
First and only PARP inhibitor to improve invasive disease-free survival in patients
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Silo enters into commercial evaluation license agreement for next generation liposomes
It´s the first trial to demonstrate the benefits of dual pathway inhibition
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Subscribe To Our Newsletter & Stay Updated